Design Therapeutics, Inc. (DSGN)
Last updated: 2026-10-24 18:17:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Summary
Design Therapeutics, Inc. (DSGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $10.23, with a market capitalization of $656.48M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.71 to $17.25. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$656.48M | |
$10.42 | |
$50.50 | |
$1.94 | |
$10.49 | |
159.28K | |
601.74K | |
-- | |
$17.25 | |
$5.71 | |
-- | |
-- |
Design Therapeutics, Inc. (DSGN) Latest Closing Stock Price
Design Therapeutics, Inc. (DSGN) last closed at $10.49 as of 2026-10-23 23:31:00, unchanged from the previous close of $10.49.
During the latest regular trading session, DSGN traded between $1.94 and $50.50, with a volume of 159.28K shares. The closing price was near the lower end and near the middle of its 52-week range.
Design Therapeutics, Inc. (DSGN) 7-Day Stock Price Change
Over the past seven days, Design Therapeutics, Inc. (DSGN) moved from $10.48 to $10.23, representing a decline of 2.39% ($0.25).
The stock traded between $9.81 and $13.58 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 444.08 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
DSGN 52-Week Price Position
Position in Range: 39.2%
DSGN is currently trading at $10.23, placing it 39.2% of the way from its 52-week low of $5.71 to its 52-week high of $17.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Design Therapeutics, Inc. (DSGN)?
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
Design Therapeutics, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 55 |
| Exchange | NASDAQ |
| Company Website |
How to Buy Design Therapeutics, Inc. (DSGN) Stock on MEXC
Eligible investors can buy real shares of Design Therapeutics, Inc. (DSGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Design Therapeutics, Inc. (DSGN) stock price today?
2.Is DSGN stock going up or down today?
3.What is DSGN pre-market price?
4.What is DSGN after-hours price?
5.Is DSGN stock trading now?
6.Where does DSGN sit relative to its 52-week high and low?
7.What sector is Design Therapeutics, Inc. in?
8.What is Design Therapeutics, Inc.'s market capitalization and where is it listed?
9.How is DSGN valued in terms of P/E ratio and EPS?
10.Does Design Therapeutics, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
DSGN Stock Calculator
Estimate the value between DSGN shares and USD.
DSGN Shares to USD
1.00 DSGN shares = 10.23 USD
Calculations are estimates based on the latest available price and are for reference only.


